Company Profile

Synovics Pharmaceuticals Inc (AKA: Lipogenics Inc~Bionutrics Inc)
Profile last edited on: 5/1/2008      CAGE:       UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
1983
First Award
1999
Latest Award
1999
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

5360 Northwest 35th Avenue
Ft. Lauderdale, FL 33309
   (954) 486-4590
   webmaster@bionutrics.com
   www.bionutrics.com
Location: Single
Congr. District: 20
County: Broward

Public Profile

As one of three subsiduaries of the OTC traded firm Bionutrics, Inc. (same address), LipoGenics, Inc is the product research arm of the Company with a focus on the discovery and development of active compounds for both drugs and functional nutrition. In addition, the Company has three inactive subsidiaries, Nutrition Technology Corporation, InCon International Ltd. and Cosmedics, Inc. Bionutrics, Inc. is a biopharmaceutical company founded to discover, develop and apply biologically active compounds from natural sources. The Company is developing proprietary functional nutrition ingredients and pharmaceutical products and intends to market these products through strategic alliances. To date the Company’s only product is the evolvE dietary supplement, containing a patented tocotrienol vitamin E ingredient, Clearesterol(TM), derived from rice bran. The Company claims that this product is effective in promoting normal cardiovascular health. The Company also claims to have additional patent rights for the use of a timed-released composition of niacin and dietary fiber, which may have applications of lowering cholesterol and benefiting diabetics and for the use of tocotrienols to treat cancer.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
100-149
Revenue Range
10M-15M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
OTC : SYVC
IP Holdings
10-14

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1999 1 NIH $122,619
Project Title: A Novel Tocotrienol For Treating Diabetic Dyslipidemia

Key People / Management

  Ronald H Lane -- President

  F H Schneider

Company News

There are no news available.